Prospective evaluation of lymphoma response to immunomodulatory therapy criteria in GATA trial from the LYSA group

Affiliations

• ¹ Nuclear Medicine Center, Scintidoc, Montpellier, France.
• ² Hematology, Le Centre Hospitalier Universitaire (CHU) François Mitterrand, Dijon, France.
• ³ Nuclear Medicine, CHU Lille, Lille, France.
• ⁴ Hematology, CHU Lyon, Lyon, France.
• ⁵ Hematology, Centre de Recherche en Cancerologie de Lyon, Lyon, France.
• ⁶ Hematology, Institut Paoli-Calmettes, Marseille, France.
• ⁷ Nuclear Medicine, CHU Nantes, Nantes, France.
• ⁸ Team 9, Centre de Recherche Clinique de Toulouse, Toulouse, France.
• ⁹ Hematology, CHU Poitiers, Poitiers, France.
• ¹⁰ Hematology and cell therapy Department, CIC INSERM U1415, CHU Tours, University of Tours, Tours, France.
• ¹¹ Hematology, CHU Grenoble, Grenoble, France.
• ¹² Hematology, CHD Vendée, La Roche sur Yon, France.
• ¹³ Hematology, Oncopole Toulouse, Toulouse, France.
• ¹⁴ Hematology, CHU Nantes, Nantes, France.
• ¹⁵ Hematology, Centre Henri Becquerel, Rouen, France.
• ¹⁶ Hematology, CHU Rennes, Rennes, France.
• ¹⁷ Hematology, CHU Lille, Lille, France.
• ¹⁸ Hematology, CHU Montpellier, Montpellier, France.